伏诺拉生-阿莫西林双联疗法在HIV感染者中根除幽门螺杆菌的疗效与安全性
本研究纳入201例接受抗逆转录病毒治疗(ART)的初治幽门螺杆菌阳性HIV感染者,给予伏诺拉生(20 mg 每日两次)联合阿莫西林(1000 mg 每日三次)治疗14天。意向性分析根除率为74.6%,符合方案分析为90.6%,不良反应发生率5.0%,表明该双联疗法作为一线治疗具有良好的疗效和安全性。
要点
- 伏诺拉生-阿莫西林双联疗法14天在HIV感染者中根除率:意向性分析74.6%,符合方案分析90.6%。
- 不良反应发生率5.0%,多为轻度且可自行缓解。
- 良好依从性与根除疗效独立相关(OR 1.03,95%CI 1.01-1.11,P<.001)。
核心结论
- 伏诺拉生-阿莫西林双联疗法作为接受ART的HIV感染者幽门螺杆菌感染的一线治疗,显示出良好的疗效和安全性。
研究设计与样本
- 单臂研究,纳入201例接受ART的初治幽门螺杆菌阳性HIV感染者,给予伏诺拉生20 mg每日两次联合阿莫西林1000 mg每日三次治疗14天。
- 治疗后至少4周采用尿素呼气试验评估根除状态,记录依从性和不良反应。
主要发现
- 根除率:意向性分析74.6%(150/201),改良意向性分析82.9%(150/181),符合方案分析90.6%(145/160)。
- 10例(5.0%)发生不良反应,包括腹胀5例,腹痛、恶心、腹泻、乏力、皮疹各1例,多为轻度且自行缓解。
- 良好依从性与疗效独立相关(OR 1.03,95%CI 1.01-1.11,P<.001)。
关键数值与推荐
- 伏诺拉生20 mg每日两次联合阿莫西林1000 mg每日三次,疗程14天。
- 根除评估在治疗结束后至少4周进行尿素呼气试验。
临床怎么用
- 对于接受ART的HIV感染者,伏诺拉生-阿莫西林双联疗法可作为幽门螺杆菌感染的一线治疗选择,需关注依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiretroviral therapy (ART) has significantly increased the life expectancy of people living with human immunodeficiency virus (PLWH), resulting in a growing need for the treatment of Helicobacter pylori infections in this population. H. pylori treament among PLWH who are on ART can be challenging due to potential drug-drug interactions (H. pylori eradication drugs interact with ART drugs). This study aimed to evaluate the efficacy and safety of vonoprazan-amoxicillin (VA) dual therapy for H. pylori infection among PLWH. METHODS: A total of 201 treatment-naive, H. pylori--positive PLWH on ART were enrolled to receive vonoprazan (20 mg twice daily) plus amoxicillin (1000 mg 3 times daily) for 14 days. H. pylori eradication status was assessed using the urease breath test ≥4 weeks after treatment. Patient compliance and adverse events (AEs) were recorded. RESULTS: Of the 201 participants, 181 (90.0%) completed the treatment course. Nineteen patients were lost to follow-up, and 1 discontinued treatment due to a rash. The eradication rates were 74.6% (150 of 201) by intention-to-treat analysis, 82.9% (150 of 181) by modified intention-to-treat analysis, and 90.6% (145 of 160) by per-protocol analysis. AEs occurred in 10 patients (5.0%), including abdominal distension in 5 and abdominal pain, nausea, diarrhea, fatigue, and rash, each occurring in 1 patient. Most AEs were mild and resolved spontaneously after treatment. Good compliance (odds ratio, 1.03 [95% confidence interval, 1.01-1.11]; P < .001) was independently associated with the efficacy of VA for H. pylori eradication. CONCLUSIONS: VA dual therapy as a first-line treatment for H. pylori infection among PLWH on ART demonstrates good efficacy and safety. CLINICAL TRIALS REGISTRATION: ChiCTR2400085762.
引用
- Zhang J, Wang Y, Chen L, et al. Efficacy and Safety of Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Infection Among People Living With HIV. J Infect Dis. 2025. PMID: 41264391. doi:10.1093/infdis/jiaf386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。